Metformin adherence lowers dementia risk in patients with type 2 diabetes – Medical Dialogues

Taiwan: Metformin provides further benefits in lowering dementia risk, and beyond conventional blood sugar control despite the launch of several new oral anti-glycemic agents, a recent study has stated. The study appeared online in the journal Endocrine Practice on 16 January 2023.
Metformin has remained among the most popular oral hypoglycemic drugs for the past 60 years. It is still the first-line medication for the initial therapy for most patients with type 2 diabetes mellitus (T2DM). In recent years, the approval of a large number of new hypoglycemic drugs has brought more options for the therapy of T2DM patients, including DPP-4i (dipeptidyl peptidase-4 inhibitors), GLP-1RA (glucagon-like peptide 1 receptor agonists), and SGLT-2i (sodium-glucose cotransporter 2 inhibitors).
Metformin is a commonly used first-line drug for patients with type 2 diabetes and has several benefits other than lowering blood sugar levels. However, since the launch of powerful glucose-lowering anti-glycemic agents, the metformin-retained regimen has been challenged. Therefore, Po-Chih Chen from Taipei Medical University, Taipei, Taiwan, and colleagues investigated the association between metformin adherence and the risk of Parkinson’s disease (PD) and dementia in a population-based cohort study.
For this purpose, the researchers identified diabetic patients with metformin-included combination anti-glycemic therapy from the National Health Insurance Research Database. The patients were then categorized into metformin-adherent and -nonadherent groups based on the medical record of the prescription’s first year. Patients with severe diabetic complications, those contraindicated with metformin and having poor drug compliance were excluded. The study outcome was a diagnosis of Parkinson’s disease or dementia.
The study led to the following findings:
“Despite the launch of several new oral anti-glycemic agents, metformin may provide further benefit in lowering dementia risk beyond conventional glycemic control as per the real-world evidence,” the researchers concluded.
Reference:
Chen, P., Hong, C., Chen, W., Chan, L., & Chien, L. (2023). Metformin adherence reduces the risk of dementia in patients with diabetes: A population-based cohort study. Endocrine Practice. https://doi.org/10.1016/j.eprac.2023.01.007
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Editorial
Journal Club Today
Health News Today

source